Richard Larson

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
van Besien Koen; Dew Alexander; Lin Shang; Joseph Loren; Godley Lucy A; Larson Richard A; Odenike Toyosi; Rich Elizabeth; Stock Wendy; Wickrema Amittha; Artz Andrew S
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
Mattison Ryan J; Larson Richard A
Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia.
Byrd John C; Byrd John C; Peterson Bercedis L; Rai Kanti R; Byrd John C; Peterson Bercedis L; Rai Kanti R; Hurd David; Hohl Raymond; Perry Michael C; Gockerman Jon; Nattam Sreenivasa; Larson Richard A
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Richard Larson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: van Besien Koen; Dew Alexander; Lin Shang; Joseph Loren; Godley Lucy A; Larson Richard A; Odenike Toyosi; Rich Elizabeth; Stock Wendy; Wickrema Amittha; Artz Andrew S
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
Leukemia & lymphoma 2009;50(11):1809-17.
2009: Mattison Ryan J; Larson Richard A
Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia.
Current opinion in oncology 2009;21(6):601-8.
2009: Byrd John C; Byrd John C; Peterson Bercedis L; Rai Kanti R; Byrd John C; Peterson Bercedis L; Rai Kanti R; Hurd David; Hohl Raymond; Perry Michael C; Gockerman Jon; Nattam Sreenivasa; Larson Richard A
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Leukemia & lymphoma 2009;50(10):1589-96.
2009: Langer Christian; Marcucci Guido; Holland Kelsi B; Radmacher Michael D; Maharry Kati; Paschka Peter; Whitman Susan P; Mrózek Krzysztof; Baldus Claudia D; Vij Ravi; Powell Bayard L; Carroll Andrew J; Kolitz Jonathan E; Caligiuri Michael A; Larson Richard A; Bloomfield Clara D
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3198-204.
2009: Mattison Ryan; Larson Richard A
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
Leukemia & lymphoma 2009;50(6):868-70.
2009: Larson Richard A
Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(1 Suppl):11-6.
2009: Poiré Xavier; Artz Andrew; Larson Richard A; Kline Justin; Odenike Olatoyosi; Rich Elizabeth; Godley Lucy; Stock Wendy; van Besien Koen
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
Leukemia & lymphoma 2009;50(1):85-91.
2008: Artz Andrew S; Wickrema Amittha; Dinner Shira; Godley Lucy A; Kocherginsky Masha; Odenike Olatoyosi; Rich Elizabeth S; Stock Wendy; Ulaszek Jodie; Larson Richard A; van Besien Koen
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(11):1209-16.
2008: Marcucci Guido; Maharry Kati; Radmacher Michael D; Mrózek Krzysztof; Vukosavljevic Tamara; Paschka Peter; Whitman Susan P; Langer Christian; Baldus Claudia D; Liu Chang-Gong; Ruppert Amy S; Powell Bayard L; Carroll Andrew J; Caligiuri Michael A; Kolitz Jonathan E; Larson Richard A; Bloomfield Clara D
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5078-87.
2008: Metzeler Klaus H; Hummel Manuela; Bloomfield Clara D; Spiekermann Karsten; Braess Jan; Sauerland Maria-Cristina; Heinecke Achim; Radmacher Michael; Marcucci Guido; Whitman Susan P; Maharry Kati; Paschka Peter; Larson Richard A; Berdel Wolfgang E; Büchner Thomas; Wörmann Bernhard; Mansmann Ulrich; Hiddemann Wolfgang; Bohlander Stefan K; Buske Christian;
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Blood 2008;112(10):4193-201.
2008: Li Zejuan; Lu Jun; Sun Miao; Mi Shuangli; Zhang Hao; Luo Roger T; Chen Ping; Wang Yungui; Yan Ming; Qian Zhijian; Neilly Mary Beth; Jin Jie; Zhang Yanming; Bohlander Stefan K; Zhang Dong-Er; Larson Richard A; Le Beau Michelle M; Thirman Michael J; Golub Todd R; Rowley Janet D; Chen Jianjun
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(40):15535-40.
2008: Baer Maria R; George Stephen L; Caligiuri Michael A; Sanford Ben L; Bothun Sandra M; Mrózek Krzysztof; Kolitz Jonathan E; Powell Bayard L; Moore Joseph O; Stone Richard M; Anastasi John; Bloomfield Clara D; Larson Richard A
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4934-9.
2008: Neubauer Andreas; Maharry Kati; Mrózek Krzysztof; Thiede Christian; Marcucci Guido; Paschka Peter; Mayer Robert J; Larson Richard A; Liu Edison T; Bloomfield Clara D
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4603-9.
2008: Paschka Peter; Marcucci Guido; Ruppert Amy S; Whitman Susan P; Mrózek Krzysztof; Maharry Kati; Langer Christian; Baldus Claudia D; Zhao Weiqiang; Powell Bayard L; Baer Maria R; Carroll Andrew J; Caligiuri Michael A; Kolitz Jonathan E; Larson Richard A; Bloomfield Clara D
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4595-602.
2008: Stock Wendy; La Mei; Sanford Ben; Bloomfield Clara D; Vardiman James W; Gaynon Paul; Larson Richard A; Nachman James;
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
Blood 2008;112(5):1646-54.
2008: Godley Lucy A; Larson Richard A
Therapy-related myeloid leukemia.
Seminars in oncology 2008;35(4):418-29.
2008: Ellis Nathan A; Huo Dezheng; Yildiz Ozlem; Worrillow Lisa J; Banerjee Mekhala; Le Beau Michelle M; Larson Richard A; Allan James M; Onel Kenan
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
Blood 2008;112(3):741-9.
2008: Stock Wendy; Undevia Samir D; Bivins Carol; Ravandi Farhad; Odenike Olatoyosi; Faderl Stefan; Rich Elizabeth; Borthakur Gautam; Godley Lucy; Verstovsek Srdan; Artz Andrew; Wierda William; Larson Richard A; Zhang Yanming; Cortes Jorge; Ratain Mark J; Giles Francis J
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Wetzler Meir; Donohue Kathleen A; Odenike Olatoyosi M; Feldman Eric J; Hurd David D; Stone Richard M; Westerfelt Peter; Bloomfield Clara D; Larson Richard A
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
Leukemia & lymphoma 2008;49(7):1274-8.
2008: Langer Christian; Radmacher Michael D; Ruppert Amy S; Whitman Susan P; Paschka Peter; Mrózek Krzysztof; Baldus Claudia D; Vukosavljevic Tamara; Liu Chang-Gong; Ross Mary E; Powell Bayard L; de la Chapelle Albert; Kolitz Jonathan E; Larson Richard A; Marcucci Guido; Bloomfield Clara D;
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Blood 2008;111(11):5371-9.
2008: Odenike Olatoyosi M; Larson Richard A; Gajria Devika; Dolan M Eileen; Delaney Shannon M; Karrison Theodore G; Ratain Mark J; Stock Wendy
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Investigational new drugs 2008;26(3):233-9.
2008: Marcucci Guido; Radmacher Michael D; Maharry Kati; Mrózek Krzysztof; Ruppert Amy S; Paschka Peter; Vukosavljevic Tamara; Whitman Susan P; Baldus Claudia D; Langer Christian; Liu Chang-Gong; Carroll Andrew J; Powell Bayard L; Garzon Ramiro; Croce Carlo M; Kolitz Jonathan E; Caligiuri Michael A; Larson Richard A; Bloomfield Clara D
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
The New England journal of medicine 2008;358(18):1919-28.
2008: Larson Richard A; Druker Brian J; Guilhot Francois; O'Brien Stephen G; Riviere Gilles J; Krahnke Tillmann; Gathmann Insa; Wang Yanfeng;
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Blood 2008;111(8):4022-8.
2008: Gordon Melinda K; Sher Dorie; Karrison Theodore; Kebriaei Partow; Chuang Karen; Zhang Yanming; McDonnell Diane; Artz Andrew; Godley Lucy; Odenike Olatoyosi; Rich Elizabeth; Michaelis Laura; Thirman Michael J; Wickrema Amittha; van Besien Koen; Larson Richard A; Stock Wendy
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Leukemia & lymphoma 2008;49(3):531-7.
2008: Whitman Susan P; Ruppert Amy S; Radmacher Michael D; Mrózek Krzysztof; Paschka Peter; Langer Christian; Baldus Claudia D; Wen Jing; Racke Frederick; Powell Bayard L; Kolitz Jonathan E; Larson Richard A; Caligiuri Michael A; Marcucci Guido; Bloomfield Clara D
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
Blood 2008;111(3):1552-9.
2007: Larson Richard A
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Seminars in oncology 2007;34(6 Suppl 5):S13-20.
2007: Mi Shuangli; Lu Jun; Sun Miao; Li Zejuan; Zhang Hao; Neilly Mary Beth; Wang Yungui; Qian Zhijian; Jin Jie; Zhang Yanming; Bohlander Stefan K; Le Beau Michelle M; Larson Richard A; Golub Todd R; Rowley Janet D; Chen Jianjun
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(50):19971-6.
2007: Hill Brian T; Kondapalli Lavayna; Artz Andrew; Smith Sonali; Rich Elizabeth; Godley Lucy; Odenike Olatoyosi; Pursell Kenneth J; Larson Richard A; Stock Wendy; van Besien Koen
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
Leukemia & lymphoma 2007;48(9):1799-805.
2007: Marcucci Guido; Maharry Kati; Whitman Susan P; Vukosavljevic Tamara; Paschka Peter; Langer Christian; Mrózek Krzysztof; Baldus Claudia D; Carroll Andrew J; Powell Bayard L; Kolitz Jonathan E; Larson Richard A; Bloomfield Clara D;
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3337-43.
2007: Whitman Susan P; Ruppert Amy S; Marcucci Guido; Mrózek Krzysztof; Paschka Peter; Langer Christian; Baldus Claudia D; Wen Jing; Vukosavljevic Tamara; Powell Bayard L; Carroll Andrew J; Kolitz Jonathan E; Larson Richard A; Caligiuri Michael A; Bloomfield Clara D
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
Blood 2007;109(12):5164-7.
2007: Wetzler Meir; Sanford Ben L; Kurtzberg Joanne; DeOliveira Divino; Frankel Stanley R; Powell Bayard L; Kolitz Jonathan E; Bloomfield Clara D; Larson Richard A
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Blood 2007;109(10):4164-7.
2007: Larson Richard A
Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Best practice & research. Clinical haematology 2007;20(1):29-37.
2007: Grever Michael R; Lucas David M; Dewald Gordon W; Neuberg Donna S; Reed John C; Kitada Shinichi; Flinn Ian W; Tallman Martin S; Appelbaum Frederick R; Larson Richard A; Paietta Elisabeth; Jelinek Diane F; Gribben John G; Byrd John C
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):799-804.
2007: Singh Zeba N; Huo Dezheng; Anastasi John; Smith Sonali M; Karrison Theodore; Le Beau Michelle M; Larson Richard A; Vardiman James W
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
American journal of clinical pathology 2007;127(2):197-205.
2006: Kline Justin; Larson Richard A
Nelarabine in the treatment of refractory T-cell malignant diseases.
Expert opinion on pharmacotherapy 2006;7(13):1791-9.
2006: Radmacher Michael D; Marcucci Guido; Ruppert Amy S; Mrózek Krzysztof; Whitman Susan P; Vardiman James W; Paschka Peter; Vukosavljevic Tamara; Baldus Claudia D; Kolitz Jonathan E; Caligiuri Michael A; Larson Richard A; Bloomfield Clara D;
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
Blood 2006;108(5):1677-83.
2006: Paschka Peter; Marcucci Guido; Ruppert Amy S; Mrózek Krzysztof; Chen Hankui; Kittles Rick A; Vukosavljevic Tamara; Perrotti Danilo; Vardiman James W; Carroll Andrew J; Kolitz Jonathan E; Larson Richard A; Bloomfield Clara D;
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(24):3904-11.
2006: Farag Sherif S; Archer Kellie J; Mrózek Krzysztof; Ruppert Amy S; Carroll Andrew J; Vardiman James W; Pettenati Mark J; Baer Maria R; Qumsiyeh Mazin B; Koduru Prasad R; Ning Yi; Mayer Robert J; Stone Richard M; Larson Richard A; Bloomfield Clara D
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Blood 2006;108(1):63-73.
2006: Larson Richard A; Stone Richard M; Mayer Robert J; Schiffer Charles A
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3556s-63s.
2006: Stock Wendy; Yu Daohai; Karrison Ted; Sher Dorie; Stone Richard M; Larson Richard A; Bloomfield Clara D
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
International journal of oncology 2006;28(5):1099-103.
2006: Larson Richard A
Management of acute lymphoblastic leukemia in older patients.
Seminars in hematology 2006;43(2):126-33.
2006: Kline J; Pollyea D A; Stock W; Artz A; Rich E; Godley L; Zimmerman T; Thompson K; Pursell K; Larson R A; van Besien K
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
Bone marrow transplantation 2006;37(3):307-10.
2006: Lee Sanggyu; Chen Jianjun; Zhou Guolin; Shi Run Zhang; Bouffard Gerard G; Kocherginsky Masha; Ge Xijin; Sun Miao; Jayathilaka Nimanthi; Kim Yeong Cheol; Emmanuel Neelmini; Bohlander Stefan K; Minden Mark; Kline Justin; Ozer Ozden; Larson Richard A; LeBeau Michelle M; Green Eric D; Trent Jeffery; Karrison Theodore; Liu Piu Paul; Wang San Ming; Rowley Janet D
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(4):1030-5.
2006: Byrd John C; Gribben John G; Peterson Bercedis L; Grever Michael R; Lozanski Gerard; Lucas David M; Lampson Ben; Larson Richard A; Caligiuri Michael A; Heerema Nyla A
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):437-43.
2006: Larson Richard A
Myelodysplasia: when to treat and how.
Best practice & research. Clinical haematology 2006;19(2):293-300.
2005: Kline Justin P; Larson Richard A
Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review.
Expert opinion on pharmacotherapy 2005;6(15):2711-8.
2005: Marcucci Guido; Baldus Claudia D; Ruppert Amy S; Radmacher Michael D; Mrózek Krzysztof; Whitman Susan P; Kolitz Jonathan E; Edwards Colin G; Vardiman James W; Powell Bayard L; Baer Maria R; Moore Joseph O; Perrotti Danilo; Caligiuri Michael A; Carroll Andrew J; Larson Richard A; de la Chapelle Albert; Bloomfield Clara D
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9234-42.
2005: Flinn Ian W; Byrd John C; Bartlett Nancy; Kipps Thomas; Gribben John; Thomas Deborah; Larson Richard A; Rai Kanti; Petric Rosemary; Ramon-Suerez Jose; Gabrilove Janice; Grever Michael R
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
Leukemia research 2005;29(11):1253-7.
2005: Larson Richard A; Sievers Eric L; Stadtmauer Edward A; Löwenberg Bob; Estey Elihu H; Dombret Hervé; Theobald Matthias; Voliotis Dimitris; Bennett John M; Richie Maria; Leopold Lance H; Berger Mark S; Sherman Matthew L; Loken Michael R; van Dongen Jacques J M; Bernstein Irwin D; Appelbaum Frederick R
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Cancer 2005;104(7):1442-52.
2005: Marcucci Guido; Mrózek Krzysztof; Ruppert Amy S; Maharry Kati; Kolitz Jonathan E; Moore Joseph O; Mayer Robert J; Pettenati Mark J; Powell Bayard L; Edwards Colin G; Sterling Lisa J; Vardiman James W; Schiffer Charles A; Carroll Andrew J; Larson Richard A; Bloomfield Clara D
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5705-17.
2005: van Besien Koen; Artz A; Smith S; Cao D; Rich S; Godley L; Jones D; Del Cerro P; Bennett D; Casey B; Odenike O; Thirman M; Daugherty C; Wickrema A; Zimmerman T; Larson R A; Stock W
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5728-38.
2005: Byrd John C; Peterson Bercedis L; Gabrilove Janice; Odenike Olatoyosi M; Grever Michael R; Rai Kanti; Larson Richard A;
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4176-81.
2005: Larson Richard A; Le Beau Michelle M
Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
Chemico-biological interactions 2005;153-154():187-95.
2005: Marcucci Guido; Stock Wendy; Dai Guowei; Klisovic Rebecca B; Liu Shujun; Klisovic Marko I; Blum William; Kefauver Cheryl; Sher Dorie A; Green Margaret; Moran Mollie; Maharry Kati; Novick Steven; Bloomfield Clara D; Zwiebel James A; Larson Richard A; Grever Michael R; Chan Kenneth K; Byrd John C
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3404-11.
2005: Kebriaei P; Kline J; Stock W; Kasza K; Le Beau M M; Larson R A; van Besien K
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Bone marrow transplantation 2005;35(10):965-70.
2005: Moore Joseph O; George Stephen L; Dodge Richard K; Amrein Philip C; Powell Bayard L; Kolitz Jonathan E; Baer Maria R; Davey Frederick R; Bloomfield Clara D; Larson Richard A; Schiffer Charles A
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
Blood 2005;105(9):3420-7.
2005: Farag Sherif S; Ruppert Amy S; Mrózek Krzysztof; Mayer Robert J; Stone Richard M; Carroll Andrew J; Powell Bayard L; Moore Joseph O; Pettenati Mark J; Koduru Prasad R K; Stamberg Judith; Baer Maria R; Block Annemarie W; Vardiman James W; Kolitz Jonathan E; Schiffer Charles A; Larson Richard A; Bloomfield Clara D
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):482-93.
2005: Byrd John C; Rai Kanti; Peterson Bercedis L; Appelbaum Frederick R; Morrison Vicki A; Kolitz Jonathan E; Shepherd Lois; Hines John D; Schiffer Charles A; Larson Richard A
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Blood 2005;105(1):49-53.
2004: Zimmerman Todd M; Harlin Helena; Odenike Olatoyosi M; Berk Seth; Sprague Evie; Karrison Theodore; Stock Wendy; Larson Richard A; Ratain Mark J; Gajewski Thomas F
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4816-22.
2004: Odenike Olatoyosi M; Sobecks Ronald M; Janisch Linda; Huo Dezheng; Zimmerman Todd M; Daugherty Christopher K; Ratain Mark J; Larson Richard A
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Cancer chemotherapy and pharmacology 2004;54(6):553-61.
2004: Kolitz Jonathan E; George Stephen L; Dodge Richard K; Hurd David D; Powell Bayard L; Allen Steven L; Velez-Garcia Enrique; Moore Joseph O; Shea Thomas C; Hoke Eva; Caligiuri Michael A; Vardiman James W; Bloomfield Clara D; Larson Richard A;
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4290-301.
2004: Blum William; Mrózek Krzysztof; Ruppert Amy S; Carroll Andrew J; Rao Kathleen W; Pettenati Mark J; Anastasi John; Larson Richard A; Bloomfield Clara D
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
Cancer 2004;101(6):1420-7.
2004: Farag Sherif S; Ruppert Amy S; Mrózek Krzysztof; Carroll Andrew J; Pettenati Mark J; Le Beau Michelle M; Peterson Bercedis L; Powell Bayard L; Ozer Howard; Silver Richard T; Larson Richard A; Bloomfield Clara D;
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
International journal of oncology 2004;25(1):143-51.
2004: Larson Richard A
Adult ALL: where are we and where are we going?
Clinical advances in hematology & oncology : H&O 2004;2(6):342-4.
2004: Marcucci Guido; Mrózek Krzysztof; Ruppert Amy S; Archer Kellie J; Pettenati Mark J; Heerema Nyla A; Carroll Andrew J; Koduru Prasad R K; Kolitz Jonathan E; Sterling Lisa J; Edwards Colin G; Anastasi John; Larson Richard A; Bloomfield Clara D
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2410-8.
2004: Sekeres Mikkael A; Peterson Bercedis; Dodge Richard K; Mayer Robert J; Moore Joseph O; Lee Edward J; Kolitz Jonathan; Baer Maria R; Schiffer Charles A; Carroll Andrew J; Vardiman James W; Davey Frederick R; Bloomfield Clara D; Larson Richard A; Stone Richard M;
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.
Blood 2004;103(11):4036-42.
2004: Kebriaei Partow; Winter Jane N; Laport Ginna G; Le Beau Michelle M; Dewald Gordon; Larson Richard A
Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation.
Leukemia research 2004;28(5):537-40.
2004: Rizzieri David A; Johnson Jeffrey L; Niedzwiecki Donna; Lee Edward J; Vardiman James W; Powell Bayard L; Barcos Maurice; Bloomfield Clara D; Schiffer Charles A; Peterson Bruce A; Canellos George P; Larson Richard A
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
Cancer 2004;100(7):1438-48.
2004: Byrd John C; Ruppert Amy S; Mrózek Krzysztof; Carroll Andrew J; Edwards Colin G; Arthur Diane C; Pettenati Mark J; Stamberg Judith; Koduru Prasad R K; Moore Joseph O; Mayer Robert J; Davey Frederick R; Larson Richard A; Bloomfield Clara D
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1087-94.
2004: Wetzler Meir; Dodge Richard K; Mrózek Krzysztof; Stewart Carleton C; Carroll Andrew J; Tantravahi Ramana; Vardiman James W; Larson Richard A; Bloomfield Clara D
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.
British journal of haematology 2004;124(3):275-88.
2004: Larson R A
The U.S. trials in adult acute lymphoblastic leukemia.
Annals of hematology 2004;83 Suppl 1():S127-8.
2004: Kolitz J E; George S L; Baer M R; Lee E J; Bloomfield C D; Larson R A;
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Annals of hematology 2004;83 Suppl 1():S103-4.
2004: Marcucci G; Stock W; Dai G; Klisovic M I; Maharry K; Shen T; Liu S; Sher D A; Lucas D; Zwiebel A; Larson R A; Caligiuri M A; Bloomfield C D; Chan K K; Grever M R; Byrd J C
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Annals of hematology 2004;83 Suppl 1():S93-4.
2004: Bloomfield C D; Ruppert A S; Mrózek K; Kolitz J E; Moore J O; Mayer R J; Edwards C G; Sterling L J; Vardiman J W; Carroll A J; Pettenati M J; Stamberg J; Byrd J C; Marcucci G; Larson R A;
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
Annals of hematology 2004;83 Suppl 1():S84-5.
2003: Larson R A; Daley G Q; Schiffer C A; Porcu P; Pui C-H; Marie J-P; Steelman L S; Bertrand F E; McCubrey J A
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(12):2358-82.
2003: Baldus Claudia D; Tanner Stephan M; Ruppert Amy S; Whitman Susan P; Archer Kellie J; Marcucci Guido; Caligiuri Michael A; Carroll Andrew J; Vardiman James W; Powell Bayard L; Allen Steven L; Moore Joseph O; Larson Richard A; Kolitz Jonathan E; de la Chapelle Albert; Bloomfield Clara D
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
Blood 2003;102(5):1613-8.
2003: Kebriaei Partow; Larson Richard A
Progress and challenges in the therapy of adult acute lymphoblastic leukemia.
Current opinion in hematology 2003;10(4):284-9.
2003: Smith Sonali M; Le Beau Michelle M; Huo Dezheng; Karrison Theodore; Sobecks Ronald M; Anastasi John; Vardiman James W; Rowley Janet D; Larson Richard A
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
Blood 2003;102(1):43-52.
2003: Larson R A
Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(3):488-91.
2003: Szatrowski Ted P; Dodge Richard K; Reynolds Carol; Westbrook Carol A; Frankel Stanley R; Sklar Jeffrey; Stewart Carleton C; Hurd David D; Kolitz Jonathan E; Velez-Garcia Enrique; Stone Richard M; Bloomfield Clara D; Schiffer Charles A; Larson Richard A
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Cancer 2003;97(6):1471-80.
2003: Byrd J C; Peterson B; Piro L; Saven A; Vardiman J W; Larson R A; Schiffer C
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(2):323-7.
2003: Silver Richard T; Peterson Bercedis L; Szatrowski Ted P; Powell Bayard L; Stock Wendy; Carroll Andrew J; Bloomfield Clara D; Schiffer Charles A; Larson Richard A
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Leukemia & lymphoma 2003;44(1):39-48.
2003: Byrd John C; Peterson Bercedis L; Morrison Vicki A; Park Kathleen; Jacobson Robert; Hoke Eva; Vardiman James W; Rai Kanti; Schiffer Charles A; Larson Richard A
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
Blood 2003;101(1):6-14.
2002: Kebriaei Partow; Anastasi John; Larson Richard A
Acute lymphoblastic leukaemia: diagnosis and classification.
Best practice & research. Clinical haematology 2002;15(4):597-621.
2002: Byrd John C; Mrózek Krzysztof; Dodge Richard K; Carroll Andrew J; Edwards Colin G; Arthur Diane C; Pettenati Mark J; Patil Shivanand R; Rao Kathleen W; Watson Michael S; Koduru Prasad R K; Moore Joseph O; Stone Richard M; Mayer Robert J; Feldman Eric J; Davey Frederick R; Schiffer Charles A; Larson Richard A; Bloomfield Clara D;
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Blood 2002;100(13):4325-36.
2002: Qian Zhijian; Fernald Anthony A; Godley Lucy A; Larson Richard A; Le Beau Michelle M
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(23):14925-30.
2002: Farag Sherif S; Archer Kellie J; Mrózek Krzysztof; Vardiman James W; Carroll Andrew J; Pettenati Mark J; Moore Joseph O; Kolitz Jonathan E; Mayer Robert J; Stone Richard M; Larson Richard A; Bloomfield Clara D
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
International journal of oncology 2002;21(5):1041-51.
2002: Farag Sherif S; George Stephen L; Lee Edward J; Baer Maria; Dodge Richard K; Becknell Brian; Fehniger Todd A; Silverman Lewis R; Crawford Jeffrey; Bloomfield Clara D; Larson Richard A; Schiffer Charles A; Caligiuri Michael A
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2812-9.
2002: Morrison Vicki A; Rai Kanti R; Peterson Bercedis L; Kolitz Jonathan E; Elias Laurence; Appelbaum Frederick R; Hines John D; Shepherd Lois; Larson Richard A; Schiffer Charles A
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3878-84.
2002: Larson R A; Boogaerts M; Estey E; Karanes C; Stadtmauer E A; Sievers E L; Mineur P; Bennett J M; Berger M S; Eten C B; Munteanu M; Loken M R; Van Dongen J J M; Bernstein I D; Appelbaum F R;
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(9):1627-36.
2002: Baer Maria R; George Stephen L; Dodge Richard K; O'Loughlin Kieran L; Minderman Hans; Caligiuri Michael A; Anastasi John; Powell Bayard L; Kolitz Jonathan E; Schiffer Charles A; Bloomfield Clara D; Larson Richard A
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Blood 2002;100(4):1224-32.
2002: Martell Robert E; Peterson Bercedis L; Cohen Harvey Jay; Petros William P; Rai Kanti R; Morrison Vicki A; Elias Laurence; Shepherd Lois; Hines John; Larson Richard A; Schiffer Charles A; Hurwitz Herbert I
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
Cancer chemotherapy and pharmacology 2002;50(1):37-45.
2002: Zhang Yanming; Strissel Pamela; Strick Reiner; Chen Jianjun; Nucifora Giuseppina; Le Beau Michelle M; Larson Richard A; Rowley Janet D
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(5):3070-5.
2001: Whitman S P; Archer K J; Feng L; Baldus C; Becknell B; Carlson B D; Carroll A J; Mrózek K; Vardiman J W; George S L; Kolitz J E; Larson R A; Bloomfield C D; Caligiuri M A
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
Cancer research 2001;61(19):7233-9.
2001: Morrison V A; Rai K R; Peterson B L; Kolitz J E; Elias L; Appelbaum F R; Hines J D; Shepherd L; Martell R E; Larson R A; Schiffer C A
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(16):3611-21.
2001: Larson R A
Current use and future development of gemtuzumab ozogamicin.
Seminars in hematology 2001;38(3 Suppl 6):24-31.
2001: Sievers E L; Larson R A; Stadtmauer E A; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett J M; Sherman M L; Berger M S; Eten C B; Loken M R; van Dongen J J; Bernstein I D; Appelbaum F R;
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3244-54.
2001: Siston A K; List M A; Daugherty C K; Banik D M; Menke C; Cornetta K; Larson R A
Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation.
Bone marrow transplantation 2001;27(11):1181-8.
2001: Baer M R; Stewart C C; Dodge R K; Leget G; Sulé N; Mrózek K; Schiffer C A; Powell B L; Kolitz J E; Moore J O; Stone R M; Davey F R; Carroll A J; Larson R A; Bloomfield C D
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Blood 2001;97(11):3574-80.
2001: Mrózek K; Prior T W; Edwards C; Marcucci G; Carroll A J; Snyder P J; Koduru P R; Theil K S; Pettenati M J; Archer K J; Caligiuri M A; Vardiman J W; Kolitz J E; Larson R A; Bloomfield C D
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2482-92.
2001: Cataland S R; Daugherty C K; Weseman E C; Larson R A
Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia.
Leukemia & lymphoma 2001;41(3-4):297-307.
2001: Larson R A
New agents for induction and postremission therapy of acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(4):675-6.
2001: Lai F; Godley L A; Joslin J; Fernald A A; Liu J; Espinosa R; Zhao N; Pamintuan L; Till B G; Larson R A; Qian Z; Le Beau M M
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).
Genomics 2001;71(2):235-45.
2000: Larson R A
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B.
Hematology/oncology clinics of North America 2000;14(6):1367-79, x.
2000: Rai K R; Peterson B L; Appelbaum F R; Kolitz J; Elias L; Shepherd L; Hines J; Threatte G A; Larson R A; Cheson B D; Schiffer C A
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
The New England journal of medicine 2000;343(24):1750-7.
2000: Larson R A
Myeloid leukemia after cytotoxic therapy and other hematotoxins.
Journal of toxicology and environmental health. Part A 2000;61(5-6):381-6.
2000: Wang P W; Eisenbart J D; Espinosa R; Davis E M; Larson R A; Le Beau M M
Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map.
Genomics 2000;67(1):28-39.
2000: Sobecks R M; Daugherty C K; Hallahan D E; Laport G F; Wagner N D; Larson R A
A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Bone marrow transplantation 2000;25(8):807-13.
2000: Hensley M L; Peterson B; Silver R T; Larson R A; Schiffer C A; Szatrowski T P
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1301-8.
1999: Larson R A; Wang Y; Banerjee M; Wiemels J; Hartford C; Le Beau M M; Smith M T
Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Blood 1999;94(2):803-7.
1999: Wetzler M; Dodge R K; Mrózek K; Carroll A J; Tantravahi R; Block A W; Pettenati M J; Le Beau M M; Frankel S R; Stewart C C; Szatrowski T P; Schiffer C A; Larson R A; Bloomfield C D
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.
Blood 1999;93(11):3983-93.
1999: Czuczman M S; Dodge R K; Stewart C C; Frankel S R; Davey F R; Powell B L; Szatrowski T P; Schiffer C A; Larson R A; Bloomfield C D
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.
Blood 1999;93(11):3931-9.
1999: Toljanic J A; Bedard J F; Larson R A; Fox J P
A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer.
Cancer 1999;85(8):1843-8.
1999: Finiewicz K J; Larson R A
Dose-intensive therapy for adult acute lymphoblastic leukemia.
Seminars in oncology 1999;26(1):6-20.
1998: Roulston D; Espinosa R; Nucifora G; Larson R A; Le Beau M M; Rowley J D
CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy.
Blood 1998;92(8):2879-85.
1998: Larson R A; Dodge R K; Linker C A; Stone R M; Powell B L; Lee E J; Schulman P; Davey F R; Frankel S R; Bloomfield C D; George S L; Schiffer C A
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
Blood 1998;92(5):1556-64.
1998: Allen R J; Smith S D; Moldwin R L; Lu M M; Giordano L; Vignon C; Suto Y; Harden A; Tomek R; Veldman T; Ried T; Larson R A; Le Beau M M; Rowley J D; Zeleznik-Le N
Establishment and characterization of a megakaryoblast cell line with amplification of MLL.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(7):1119-27.
1998: Larson R A; Fretzin M H; Dodge R K; Schiffer C A
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(5):660-5.
1998: Dann E J; Anastasi J; Larson R A
High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1498-504.
1998: Anastasi J; Musvee T; Roulston D; Domer P H; Larson R A; Vardiman J W
Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(2):233-7.
1998: Lee M Y; Jensen E; Kwak S; Larson R A
Metastatic adenocarcinoma arising in a congenital foregut cyst of the esophagus: a case report with review of the literature.
American journal of clinical oncology 1998;21(1):64-6.
1997: Wang P; Spielberger R T; Thangavelu M; Zhao N; Davis E M; Iannantuoni K; Larson R A; Le Beau M M
dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
Genes, chromosomes & cancer 1997;20(3):282-91.
1997: Dann E J; Daugherty C K; Larson R A
Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Bone marrow transplantation 1997;20(5):369-74.
1997: Zhao N; Stoffel A; Wang P W; Eisenbart J D; Espinosa R; Larson R A; Le Beau M M
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(13):6948-53.
1997: Laport G F; Larson R A
Treatment of adult acute lymphoblastic leukemia.
Seminars in oncology 1997;24(1):70-82.
1996: Larson R A; LeBeau M M; Vardiman J W; Rowley J D
Myeloid leukemia after hematotoxins.
Environmental health perspectives 1996;104 Suppl 6():1303-7.
1996: Le Beau M M; Espinosa R; Davis E M; Eisenbart J D; Larson R A; Green E D
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.
Blood 1996;88(6):1930-5.
1996: Anastasi J; Feng J; Dickstein J I; Le Beau M M; Rubin C M; Larson R A; Rowley J D; Vardiman J W
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(5):795-802.
1996: Thirman M J; Larson R A
Therapy-related myeloid leukemia.
Hematology/oncology clinics of North America 1996;10(2):293-320.
1996: Larson R A
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10 Suppl 1():S23-5.
1996: Olopade O I; Roulston D; Baker T; Narvid S; Le Beau M M; Freireich E J; Larson R A; Golomb H M
Familial myeloid leukemia associated with loss of the long arm of chromosome 5.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(4):669-74.
1996: Larson R A; Mick R; Spielberger R T; O'Brien S M; Ratain M J
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):188-95.
1995: Anastasi J; Feng J; Le Beau M M; Larson R A; Rowley J D; Vardiman J W
The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(4):628-33.
1995: Larson R A; Dodge R K; Burns C P; Lee E J; Stone R M; Schulman P; Duggan D; Davey F R; Sobol R E; Frankel S R
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Blood 1995;85(8):2025-37.
1995: Somani J; Larson R A
Reimmunization after allogeneic bone marrow transplantation.
The American journal of medicine 1995;98(4):389-98.
1995: Joventino L P; Stock W; Lane N J; Daly K M; Mick R; Le Beau M M; Larson R A
Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(3):433-9.
1995: Drinkard L C; Waggoner S; Stein R N; Byrne R A; Larson R A
Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature.
Gynecologic oncology 1995;56(2):307-11.
1995: Martinez-Climent J A; Lane N J; Rubin C M; Morgan E; Johnstone H S; Mick R; Murphy S B; Vardiman J W; Larson R A; Le Beau M M
Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(1):95-101.
1995: Larson R A; Geller R B; Janisch L; Milton J; Grochow L B; Ratain M J
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Cancer chemotherapy and pharmacology 1995;36(3):204-10.
1994: Stock W; Thirman M J; Dodge R K; Rowley J D; Diaz M O; Wurster-Hill D; Sobol R E; Davey F R; Larson R A; Westbrook C A
Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(11):1918-22.
1994: Downie P A; Vogelzang N J; Moldwin R L; Le Beau M M; Anastasi J; Allen R J; Myers S E; Larson R A; Smith S D
Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia.
Cancer research 1994;54(18):4999-5004.
1994: Platanias L C; Ratain M J; O'Brien S; Larson R A; Vardiman J W; Shaw J P; Williams S F; Baron J M; Parker K; Woodworth T G
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Leukemia & lymphoma 1994;14(3-4):257-62.
1993: Super H J; McCabe N R; Thirman M J; Larson R A; Le Beau M M; Pedersen-Bjergaard J; Philip P; Diaz M O; Rowley J D
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
Blood 1993;82(12):3705-11.
1993: Nucifora G; Larson R A; Rowley J D
Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission.
Blood 1993;82(3):712-5.
1993: Le Beau M M; Espinosa R; Neuman W L; Stock W; Roulston D; Larson R A; Keinanen M; Westbrook C A
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(12):5484-8.
1993: Raza A; Preisler H D; Browman G P; Larson R A; Rustum Y M; Goldberg J; Vogler R; Miller K A; Bennett J; Kukla C
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.
Leukemia & lymphoma 1993;10(1-2):57-66.
1993: Spielberger R T; Falleroni M J; Coene A J; Larson R A
Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;16(4):528-30.
1993: Raza A; Preisler H D; Li Y Q; Larson R A; Goldberg J; Browman G; Bennett J; Grunwald H; Vogler R; Kukla C
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia.
American journal of hematology 1993;42(4):359-66.
1993: Spielberger R T; Dickstein J I; Le Beau M M; Larson R A; Daly K M; Vardiman J W; Golomb H M
Acute myeloid leukaemia following interferon-alfa treatment of hairy cell leukaemia.
British journal of haematology 1993;83(3):519-20.
1993: Anastasi J; Feng J; Le Beau M M; Larson R A; Rowley J D; Vardiman J W
Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion.
Blood 1993;81(6):1580-5.
1992: Westbrook C A; Hooberman A L; Spino C; Dodge R K; Larson R A; Davey F; Wurster-Hill D H; Sobol R E; Schiffer C; Bloomfield C D
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Blood 1992;80(12):2983-90.
1992: Olopade O I; Thangavelu M; Larson R A; Mick R; Kowal-Vern A; Schumacher H R; Le Beau M M; Vardiman J W; Rowley J D
Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia.
Blood 1992;80(11):2873-82.
1992: Preisler H D; Raza A; Larson R A
Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients.
Blood 1992;80(10):2600-3.
1992: Gradishar W J; Le Beau M M; O'Laughlin R; Vardiman J W; Larson R A
Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia.
Blood 1992;80(10):2463-70.
1992: Myers S E; Devine S M; Topper R L; Ondrey M; Chandler C; O'Toole K; Williams S F; Larson R A; Geller R B
A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia.
Leukemia & lymphoma 1992;8(3):229-33.
1992: Larson R A; Day R S; Azarnia N; Bennett J M; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
British journal of haematology 1992;82(2):337-46.
1992: Anastasi J; Le Beau M M; Vardiman J W; Fernald A A; Larson R A; Rowley J D
Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method.
Blood 1992;79(7):1796-801.
1992: Neuman W L; Rubin C M; Rios R B; Larson R A; Le Beau M M; Rowley J D; Vardiman J W; Schwartz J L; Farber R A
Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders.
Blood 1992;79(6):1501-10.
1992: Geller R B; Myers S; Devine S; Larson R A; Williams S F; Park C L; O'Toole K; Chandler C; Topper R L
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
Bone marrow transplantation 1992;9(1):41-7.
1991: Preisler H D; Larson R A; Raza A; Browman G; Goldberg J; Vogler R; Day R; Gottlieb A; Vardiman J W; Bennett J
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure.
British journal of haematology 1991;79(3):390-7.
1991: Anastasi J; Thangavelu M; Vardiman J W; Hooberman A L; Bian M L; Larson R A; Le Beau M M
Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow transplantation.
Blood 1991;77(5):1087-91.
1991: Hohl R J; Larson R A; Mannickarottu V; Yachnin S
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells.
Blood 1991;77(5):1064-70.
1991: Larson R A; Lukin C L; Daly K M; Mick R; Gore S; Le Beau M M
Circulating immune complexes correlate with remission duration in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(2):131-7.
1990: Rubin C M; Larson R A; Anastasi J; Winter J N; Thangavelu M; Vardiman J W; Rowley J D; Le Beau M M
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia.
Blood 1990;76(12):2594-8.
1990: Platanias L C; Larson R A; Vardiman J W; Reisel H; Golomb H M; McKeithan T W
Complex rearrangement of the T cell receptor in large granular lymphocytosis associated with myeloid suppression.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(12):863-5.
1990: Thangavelu M; Olopade O; Beckman E; Vardiman J W; Larson R A; McKeithan T W; Le Beau M M; Rowley J D
Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11).
Genes, chromosomes & cancer 1990;2(2):147-58.
1990: Kaminer L S; Choi K E; Daley K M; Larson R A
Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
Cancer 1990;65(12):2619-23.
1990: Bitter M A; Franklin W A; Larson R A; McKeithan T W; Rubin C M; Le Beau M M; Stephens J K; Vardiman J W
Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35).
The American journal of surgical pathology 1990;14(4):305-16.
1990: Olopade O I; Larson R A; Mick R; Watson S M; Hoffman P C; Ultmann J E; Golomb H M
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(2):127-31.
1990: Diaz M O; Rubin C M; Harden A; Ziemin S; Larson R A; Le Beau M M; Rowley J D
Deletions of interferon genes in acute lymphoblastic leukemia.
The New England journal of medicine 1990;322(2):77-82.
1989: Le Beau M M; Bitter M A; Larson R A; Doane L A; Ellis E D; Franklin W A; Rubin C M; Kadin M E; Vardiman J W
The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(12):866-70.
1989: Sagher D; Karrison T; Schwartz J L; Larson R A; Strauss B
Heterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Cancer research 1989;49(19):5339-44.
1989: Williams S F; Larson R A
Hypersensitivity reaction to high-dose cytarabine.
British journal of haematology 1989;73(2):274-5.
1989: Schwartz J L; Karrison T; Le Beau M M; Larson R A; Sagher D; Strauss B; Rowley J D; Weichselbaum R R
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia.
Mutation research 1989;216(2):119-26.
1989: Le Beau M M; Lemons R S; Espinosa R; Larson R A; Arai N; Rowley J D
Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q).
Blood 1989;73(3):647-50.
1989: Thangavelu M; Bitter M A; Larson R A; Davis E M; Rowley J D; Le Beau M M
Der(5)t(5;7)(q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders.
Cancer genetics and cytogenetics 1989;37(1):1-8.
1988: Li Y S; Anastasi J; Larson R A; Le Beau M M; Vardiman J W; Rowley J D
A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia.
Cancer genetics and cytogenetics 1988;35(2):143-50.
1988: Larson R A; Wernli M; Le Beau M M; Daly K M; Pape L H; Rowley J D; Vardiman J W
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine.
Blood 1988;72(4):1333-9.
1988: Daiter S; Larson R A; Weddington W W; Ultmann J E
Psychosocial symptomatology, personal growth, and development among young adult patients following the diagnosis of leukemia or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):613-7.
1988: Robertson M J; Larson R A
Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy.
The American journal of medicine 1988;84(2):233-9.
1988: Samuels B L; Larson R A; Le Beau M M; Daly K M; Bitter M A; Vardiman J W; Barker C M; Rowley J D; Golomb H M
Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1988;2(2):79-83.
1988: Rippon J W; Larson R A; Rosenthal D M; Clayman J
Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature.
Mycopathologia 1988;101(2):105-11.
1987: Rubin C M; Larson R A; Bitter M A; Carrino J J; Le Beau M M; Diaz M O; Rowley J D
Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia.
Blood 1987;70(5):1338-42.
1987: Ratain M J; Kaminer L S; Bitran J D; Larson R A; Le Beau M M; Skosey C; Purl S; Hoffman P C; Wade J; Vardiman J W
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
Blood 1987;70(5):1412-7.
1987: Choi K E; Sinkule J A; Han D S; McGrath S C; Daly K M; Larson R A
High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection.
Journal of chromatography 1987;420(1):81-8.
1987: Pettenati M J; Le Beau M M; Lemons R S; Shima E A; Kawasaki E S; Larson R A; Sherr C J; Diaz M O; Rowley J D
Assignment of CSF-1 to 5q33.1: evidence for clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(9):2970-4.
1987: Larson R A; Daly K M; Choi K E; Han D S; Sinkule J A
A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(3):391-7.
1986: Le Beau M M; Pettenati M J; Lemons R S; Diaz M O; Westbrook C A; Larson R A; Sherr C J; Rowley J D
Assignment of the GM-CSF, CSF-1, and FMS genes to human chromosome 5 provides evidence for linkage of a family of genes regulating hematopoiesis and for their involvement in the deletion (5q) in myeloid disorders.
Cold Spring Harbor symposia on quantitative biology 1986;51 Pt 2():899-909.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Richard Larson

Research Profile (preview)

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Richard Larson (preview)

All Publications